Matches in SemOpenAlex for { <https://semopenalex.org/work/W4248156689> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W4248156689 endingPage "370" @default.
- W4248156689 startingPage "361" @default.
- W4248156689 abstract "An improved understanding regarding the pathophysiology of psoriasis, coupled with advances in molecular research, has prompted the development of targeted biologic treatments for patients with plaque psoriasis. T lymphocytes play an important role in initiating the immune system and the inflammatory responses that result in the development and maintenance of psoriatic plaques. Efalizumab (anti-CD11a, Raptiva™; Genentech, Inc.) is a mAb that targets the T cell adhesion molecule, leukocyte function-associated antigen-1 (LFA-1). By binding to CD11a – the α-subunit of LFA-1 – LFA-1 is prevented from binding with its ligand, intercellular adhesion molecule-1 (ICAM-1). This inhibits various T cell processes believed to be important in the pathogenesis of psoriasis, including T cell activation, T cell adhesion to endothelial cells and T cell migration. Clinical trials demonstrate that efalizumab, given subcutaneously once-weekly, provides clinical benefit, including improved quality of life, in patients with moderate-to-severe plaque psoriasis. Efalizumab is associated with an early onset of action, with improvement noted as early as 14 days. Studies with extended treatment suggest that continuing efalizumab therapy is more beneficial in maintaining and improving responses. Relapse of psoriasis is usually seen within 60 – 70 days after discontinuation of therapy, and rebound in ~ 5% of patients (i.e., flare to > 125% of baseline) is noted. Efalizumab is associated with acute adverse events during the first and second injections, which decrease in incidence with each subsequent injection. Data indicate that efalizumab can be safely administered for extended periods of time. Given the efficacy, early onset of clinical benefit, the safety profile and the convenience of once-weekly subcutaneous home dosing, efalizumab offers an interesting new therapeutic option for the treatment of psoriasis and the potential for improved and potentially safer long-term, continuous ‘maintenance’ therapy." @default.
- W4248156689 created "2022-05-12" @default.
- W4248156689 creator A5004761425 @default.
- W4248156689 creator A5058658647 @default.
- W4248156689 creator A5075798284 @default.
- W4248156689 date "2003-01-01" @default.
- W4248156689 modified "2023-10-18" @default.
- W4248156689 title "Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab" @default.
- W4248156689 doi "https://doi.org/10.1517/eobt.3.2.361.21144" @default.
- W4248156689 hasPublicationYear "2003" @default.
- W4248156689 type Work @default.
- W4248156689 citedByCount "2" @default.
- W4248156689 crossrefType "journal-article" @default.
- W4248156689 hasAuthorship W4248156689A5004761425 @default.
- W4248156689 hasAuthorship W4248156689A5058658647 @default.
- W4248156689 hasAuthorship W4248156689A5075798284 @default.
- W4248156689 hasConcept C171779818 @default.
- W4248156689 hasConcept C203014093 @default.
- W4248156689 hasConcept C2780564577 @default.
- W4248156689 hasConcept C2780969348 @default.
- W4248156689 hasConcept C3020604521 @default.
- W4248156689 hasConcept C53122370 @default.
- W4248156689 hasConcept C62084212 @default.
- W4248156689 hasConcept C71924100 @default.
- W4248156689 hasConcept C8891405 @default.
- W4248156689 hasConcept C98274493 @default.
- W4248156689 hasConceptScore W4248156689C171779818 @default.
- W4248156689 hasConceptScore W4248156689C203014093 @default.
- W4248156689 hasConceptScore W4248156689C2780564577 @default.
- W4248156689 hasConceptScore W4248156689C2780969348 @default.
- W4248156689 hasConceptScore W4248156689C3020604521 @default.
- W4248156689 hasConceptScore W4248156689C53122370 @default.
- W4248156689 hasConceptScore W4248156689C62084212 @default.
- W4248156689 hasConceptScore W4248156689C71924100 @default.
- W4248156689 hasConceptScore W4248156689C8891405 @default.
- W4248156689 hasConceptScore W4248156689C98274493 @default.
- W4248156689 hasIssue "2" @default.
- W4248156689 hasLocation W42481566891 @default.
- W4248156689 hasOpenAccess W4248156689 @default.
- W4248156689 hasPrimaryLocation W42481566891 @default.
- W4248156689 hasRelatedWork W1983777147 @default.
- W4248156689 hasRelatedWork W1989566109 @default.
- W4248156689 hasRelatedWork W2027978561 @default.
- W4248156689 hasRelatedWork W2039103439 @default.
- W4248156689 hasRelatedWork W2060311860 @default.
- W4248156689 hasRelatedWork W2073796343 @default.
- W4248156689 hasRelatedWork W2110483286 @default.
- W4248156689 hasRelatedWork W2116619489 @default.
- W4248156689 hasRelatedWork W2122822622 @default.
- W4248156689 hasRelatedWork W2404038155 @default.
- W4248156689 hasVolume "3" @default.
- W4248156689 isParatext "false" @default.
- W4248156689 isRetracted "false" @default.
- W4248156689 workType "article" @default.